Advertisement


Jeffrey Jones, MD, MPH, on Chronic Lymphocytic Leukemia: Optimizing Treatment With New Agents

2016 NCCN Annual Conference (1)

Advertisement

Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.



Related Videos

Lung Cancer

Douglas E. Wood, MD, on Lung Cancer Screening: Status and Patient Selection

Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.

Pain Management

Judith Paice, PhD, RN, on Managing Cancer Pain: Strategies for Prescribing Opioids

Judith Paice, PhD, RN, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses strategies for safe opioid prescribing: making a comprehensive assessment, stratifying risk, using universal precautions, and educating practitioners on safe storage and disposal.

Colorectal Cancer

Alan Venook, MD, on Metastatic Colorectal Cancer: Choosing Optimal Treatment Strategies

Alan Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses new observations on biomarkers, the best combinations of therapies, and how to sequence them.

Breast Cancer

Kevin C. Oeffinger, MD, on Controversies in Breast Cancer Screening Strategies

Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, discusses American Cancer Society recommendations, including the advice that women with an average risk of breast cancer should undergo regular screening mammography starting at age 45, and that women 55 and older should have biennial screening.

Gastroesophageal Cancer

Jaffer Ajani, MD, on Metastatic Gastroesophageal Cancers: Expert Perspective

Jaffer Ajani, MD, of The University of Texas MD Anderson Cancer Center, discusses the importance of HER2/neu testing and other aspects of treating patients with advanced gastroesophageal adenocarcinoma.

Advertisement

Advertisement




Advertisement